Zynerba Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Zynerba Pharmaceuticals

04/08/2023 16:40

* Zynerba Pharmaceuticals Inc  ZYNE.OQ   ZYNE.O  is expected
to show no change in quarterly revenue when it reports 
results on August 8 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Zynerba
Pharmaceuticals
Inc is for a loss of 20 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $7​, above​ its last closing price
of $0.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.19       -0.19      -0.21     Missed  -10.5
 Dec. 31 2023              -0.18      -0.18     Met     2.7
 Sep. 30 2022  -0.23       -0.22      -0.20     Beat    11.1​
 Jun. 30 2022  -0.23       -0.23      -0.24     Missed  -4.8
 ​​Mar.        -0.23       -0.23      -0.21     Beat    8.2
 31 2022                                                
 Dec. 31 2021  -0.26       -0.26      -0.22     Beat    16.5​
 Sep. 30 2021  -0.25       -0.25      -0.26     Missed  -3.2
 Jun. 30 2021  -0.20       -0.24      -0.25     Missed  -5
 This summary was machine generated August 4 at 15:40 GMT.  All
figures in US dollars  unless otherwise stated